The UK Department for Science, Innovation and Technology (DSIT) has set out how it will allocate £13.9 ($17.9) billion in funding for transformational research and development in the next year in areas like life sciences, green energy, engineering and beyond.  

UK Research and Innovation (UKRI) – the UK’s lead public research funder – will receive £8.8 ($11.3) billion over the next year. 

Each pound of public R&D investment is estimated to leverage double in private investment in the long run. Businesses that receive their first R&D grant funding also see jobs and turnover go up by over 20% in the following six years. 

Science and Technology Secretary, Peter Kyle, said: “Our £13.9 billion investment in R&D is ultimately an investment in the future of the UK. R&D is essential to fulfilling this government’s Plan for Change – whether in improving lives across the UK and beyond through new life-saving drugs, helping us build a cleaner, greener future or in exploring beyond our planet to unlock new discoveries that keep us healthy, safe and prosperous and much more besides.” 

Life sciences R&D

R&D funding delivered through UKRI is supporting teams at the University of Plymouth to tackle antimicrobial resistance. 

Their discovery of a new antibiotic, Epidermicin, is undergoing trials and has led to spinout company, Amprologix – potentially providing health professionals with a silver bullet in the battle against such bacterial infections whilst opening up new commercial opportunities in the UK. 

Joe Edwards, Association of the British Pharmaceutical Industry (ABPI) Director of UK Competitiveness and Devolved Nations, commented on the investment: “The research and development of new medicines and vaccines is a powerful contributor to economic growth. The pharmaceutical industry is the largest private sector investor in UK R&D, and this strength is built upon a strong foundation of world-class science.  

“Public R&D investment is one of government’s most powerful tools to boost growth and increase productivity if directed effectively. Today’s announcements offer welcome clarity for research funders at a time when inflation is putting extra pressure on R&D budgets. 

“This funding must be backed up by meaningful long-term action to support discovery science in the upcoming Life Sciences Sector Plan and Comprehensive Spending Review.”

Diana Spencer, Senior Digital Content Editor, DDW